Document is current
Any future updates will be listed below
-
Authors
Houlahan, Kathleen E. https://orcid.org/0000-0002-2273-2099
Mangiante, Lise https://orcid.org/0000-0001-8309-0950
Sotomayor-Vivas, Cristina https://orcid.org/0000-0001-8228-477X
Adimoelja, Alvina
Park, Seongyeol
Khan, Aziz https://orcid.org/0000-0002-6459-6224
Pribus, Sophia J.
Ma, Zhicheng
Caswell-Jin, Jennifer L. https://orcid.org/0000-0002-5711-8355
Curtis, Christina https://orcid.org/0000-0003-0166-3802
- License Information
-
More Information
Article History
Received: 12 March 2024
Accepted: 8 November 2024
First Online: 8 January 2025
Competing interests
: Unrelated to this work, the following interests are declared: S.P. has equity in Inocras; J.L.C.-J. holds grants from Effector Therapeutics, Novartis and QED Therapeutics; C.C. has advised Bristol Myers Squibb, DeepCell, Genentech, NanoString, Pfizer and 3T Biosciences and has equity in 3T Biosciences, DeepCell and Illumina. All other authors declare no competing interests.
